Pacira BioSciences Defends Board & Strategy Against Activist in Proxy Battle

summarizeSummary

Pacira BioSciences released an investor presentation defending its current board and "5x30 Plan" against activist investor DOMA Perpetual Capital Management, ahead of the 2026 Annual Meeting.

check_boxKey Events

• Proxy Battle Defense

  Pacira is actively soliciting votes for its board nominees and against those proposed by activist investor DOMA Perpetual Capital Management for the 2026 Annual Meeting.

• Strategic Performance Highlighted

  The company emphasized its "Pacira 2.0" transformation, record 2025 financial performance ($726.4M revenue, 81.2% Non-GAAP Gross Margins), and 22% total stockholder return since launching its "5x30 Plan."

• Capital Allocation & IP Strength

  Pacira detailed $200 million in share repurchases since April 2025 and highlighted strengthened EXPAREL patent exclusivity through 2030, extending to 2039 with gradual generic entry.

• Board & Management Qualifications

  The filing showcased a recently refreshed board with strong governance practices and presented its director nominees as highly qualified, contrasting them with DOMA's nominees.

auto_awesomeAnalysis

This filing is Pacira's detailed defense against activist investor DOMA Perpetual Capital Management, urging shareholders to vote for its nominees at the 2026 Annual Meeting. The company highlights its "Pacira 2.0" transformation, strong financial performance, progress on its "5x30 Plan," and strategic capital allocation including significant share repurchases. It also emphasizes its strengthened intellectual property for EXPAREL and a refreshed, highly qualified board. The filing strongly criticizes DOMA's engagement tactics and proposed strategy, arguing that DOMA's plan to force a sale and replace the CEO is not in the best interest of all stockholders. The outcome of this proxy contest will determine the company's future strategic direction and leadership.